Elizabeth Gardner

Hyman Muss, MD, discusses special considerations that should be taken when treating older patients with HER2-positive or triple-negative breast cancer.

HER2-positive breast cancer has gone from "worst to first" because of the success of the monoclonal antibody drug trastuzumab in combination with chemotherapy. 

Breast cancer in younger women needs a different adjuvant treatment strategy from that used in post-menopausal women, but it may not have to include suppressing ovarian function.

Figuring out how a certain genetic result found through multigene testing might change not only the type of intervention but its timing is the chief challenge, according to Mark Robson, MD, in a presentation at the 2017 Lynn Sage Breast Cancer Symposium.

Andrew Seidman, MD, discusses the Watson for Oncology application and the potential for Watson to be a valuable partner for oncologists during the 19^th Annual Lynn Sage Breast Cancer Symposium.

Judith A. Paice, PhD, RN, discusses the best way to approach pain management in breast cancer.

"We should be doing this, because we understand the disease, we see these patients, and we're not just surgeons, Dr. Adam Kibel said. "We were giving them medications to control their BPH before we diagnosed them with cancer."